DigiDiab Pilot: Impact Study Hospital

Last updated: July 29, 2025
Sponsor: Medical University of Graz
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes Mellitus Types I And Ii

Diabetes And Hypertension

Diabetes Mellitus, Type 2

Treatment

Diabetes Treatment

GlucoTab

Clinical Study ID

NCT06605872
230206 EITHealth-hospital
  • Ages > 18
  • All Genders

Study Summary

GlucoTab is an innovative workflow and decision support tool for standardised diabetes management by healthcare professionals which provides automated and personalised dosage recommendations for different insulin therapy regimens.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • informed consent obtained after being advised of the nature of the study

  • a documented history of type 2 diabetes prior to inclusion or new-onsethyperglycaemia which requires s.c. insulin therapy during hospital stay

  • admission to either surgical or internal medicine ward

  • an expected length of hospital stay for at least 48 hours after enrolment

Exclusion

Exclusion Criteria:

  • type 1 diabetes mellitus

  • intravenous insulin therapy

  • hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they requireintravenous insulin therapy

  • continuous subcutaneous insulin infusion

  • gestational diabetes or pregnancy

  • known or suspected allergy to insulin

  • total parenteral nutrition

  • any mental condition rendering the patient incapable of giving his/her consent

  • any disease or condition which according to the investigator or treating physicianwould interfere with the trial or the safety of the patient

Inclusion and exclusion criteria will be the same as above for the retrospective CG with the exception of:

  • period of time will be from September 2022 to September 2023

  • no informed consent will be obtained from the retrospective CG

Study Design

Total Participants: 500
Treatment Group(s): 2
Primary Treatment: Diabetes Treatment
Phase:
Study Start date:
April 01, 2025
Estimated Completion Date:
October 31, 2025

Study Description

GlucoTab has already been tested in several clinical trials in Austria and has consecutively obtained the CE-mark that is valid throughout European countries.

The current study aims to further develop, implement and evaluate GlucoTab in different European pilot regions. For this reason, GlucoTab will be translated in different languages and tested in Sweden, Denmark, and Spain.

Connect with a study center

  • Hospital Universitari Joan XXIII de Tarragona

    Tarragona,
    Spain

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.